> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Lupin Form 483 Released After Inspection
- URL: https://www.fdaweb.com/lupin-form-483-released-after-inspection/
- Published: 2017-04-28T12:00:00.000Z
- Updated: 2026-09-14T22:20:46.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5138577

FDA has released a three-item [Form 483 ](https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/CDERFOIAElectronicReadingRoom/UCM555428.pdf?ref=fdaweb.com)after an inspection at Lupin’s Goa, India drug manufacturing facility found GMP problems. For example, the agency said the firm failed to thoroughly review any unexplained discrepancy and the failure of a batch to meet any of its specifications. The company also invalidated numerous out-of-specification results by retesting and reporting the average results of replicate tests.

  
FDA also cited Lupin for not having appropriate written procedures for production and process controls. And it said control procedures are not established to monitor the output of those manufacturing processes that may be responsible for causing variability in the characteristics of in-process material and the drug product.